The FDA’s new, same-old food labels demand better obesity solutions
All things considered, it’s at least as likely to make health outcomes worse as it is to make most people healthier.
US FDA approves Axsome Therapeutics' migraine drug
The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday.
FDA approves new type of non-opioid pain medication
The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...
US FDA identifies cybersecurity risks in certain patient monitors
The U.S. Food and Drug Administration (FDA) said on Thursday it had identified three cybersecurity risks associated with ...
FDA approves painkiller designed to eliminate the risk of addiction associated with opioids
The FDA approved a pain drug designed to eliminate the risks associated with opioids -- the first new pharmaceutical approach ...
WNYT NewsChannel 1353m
FDA approves new nonopioid painkiller for acute pain
On Thursday, in a major step forward in pain management, the U.S. Food and Drug Administration has approved a new nonopioid ...
FDA approves new painkiller that shows promise and challenges of opioid alternatives
U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...
Do food warning labels actually work? Answering your questions.
Readers had a lot to say about my latest column on the Food and Drug Administration’s proposed front-of-package labels. Most ...
WISH-TV on MSN10h
FDA redefines ‘healthy’ food labels to help consumers make informed choices
The FDA is overhauling food labels to redefine "'healthy," focusing on redefining terms and introducing new front-of-package ...
The FDA says it has approved a new non-addictive pain medication
(CNN) – The U.S. Food and Drug Administration approved the first new type of pain medication in more than two decades, and it ...
Vertex’s non-opioid pain drug gets FDA approval in milestone for company and research
Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, potentially limiting patients’ ability to access it.